1. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).
2. Tomczak, K., Czerwińska, P. & Wiznerowicz, M. Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Współczesna Onkol. 1A, 68–77 (2015).
3. Hudson, T. J. et al. International network of cancer genome projects. Nature 464, 993–998 (2010).
4. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).
5. Garraway, L. A. & Lander, E. S. Lessons from the cancer genome. Cell 153, 17– 37 (2013).
6. Gygi, S. P., Rochon, Y., Franza, B. R. & Aebersold, R. Correlation between Protein and mRNA Abundance in Yeast. Mol. Cell. Biol. 19, 1720 LP – 1730 (1999).
7. Anderson, N. L. & Anderson, N. G. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis 19, 1853–1861 (1998).
8. Gholami, A. M. et al. Global proteome analysis of the NCI-60 cell line panel. Cell Rep. (2013) doi:10.1016/j.celrep.2013.07.018.
9. Coscia, F. et al. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat. Commun. 7, (2016).
10. Frejno, M. et al. Proteome activity landscapes of tumor cell lines determine drug responses. Nat. Commun. 11, 1–12 (2020).
11. Tyanova, S. et al. Proteomic maps of breast cancer subtypes. Nat. Commun. 7, 1– 11 (2016).
12. Nusinow, D. P. et al. Quantitative Proteomics of the Cancer Cell Line Encyclopedia. Cell 180, 387-402.e16 (2020).
13. Mertins, P. et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55–62 (2016).
14. Zhang, H. et al. Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. Cell (2016) doi:10.1016/j.cell.2016.05.069.
15. Jaffe, J. D., Berg, H. C. & Church, G. M. Proteogenomic mapping as a complementary method to perform genome annotation. Proteomics 4, 59–77 (2004).
16. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
17. Ghandi, M. et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569, 503–508 (2019).
18. Tsherniak, A. et al. Defining a Cancer Dependency Map. Cell 170, 564-576.e16 (2017).
19. Needham, E. J., Parker, B. L., Burykin, T., James, D. E. & Humphrey, S. J. Illuminating the dark phosphoproteome. Sci. Signal. 12, (2019).
20. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747– 752 (2000).
21. Sørlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U. S. A. 100, 8418–8423 (2003).
22. Bernard, P. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160–1167 (2009).
23. Ellis, M. J. et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor- rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based in. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29, 2342–2349 (2011).
24. Chia, S. K. et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin. cancer Res. an Off. J. Am. Assoc. Cancer Res. 18, 4465–4472 (2012).
25. LASFARGUES, E. Y. & OZZELLO, L. Cultivation of human breast carcinomas. J. Natl. Cancer Inst. 21, 1131–1147 (1958).
26. Koboldt, D. C. et al. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
27. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).
28. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346–352 (2012).
29. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979–993 (2012).
30. Liu, K. et al. Evaluating cell lines as models for metastatic breast cancer through integrative analysis of genomic data. Nat. Commun. 10, (2019).
31. Jiang, G. et al. Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics 17, (2016).
32. Cox, J., Yu, S. H. & Kyriakidou, P. Isobaric matching between runs and novel PSM-level normalization in maxquant strongly improve reporter ion-based quantification. J. Proteome Res. 19, 3945–3954 (2020).
33. Schwacke, J. H., Hill, E. G., Krug, E. L., Comte-Walters, S. & Schey, K. L. iQuantitator: A tool for protein expression inference using iTRAQ. BMC Bioinformatics 10, 342 (2009).
34. Herbrich, S. M. et al. Statistical inference from multiple iTRAQ experiments without using common reference standards. J. Proteome Res. 12, 594–604 (2013).
35. Yi, J. et al. Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers. Biomed. Pharmacother. 124, 109827 (2020).
36. Oki, S. et al. Ch IP ‐Atlas: a data‐mining suite powered by full integration of public Ch IP ‐seq data . EMBO Rep. 19, 1–10 (2018).
37. Carroll, J. S. et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122, 33– 43 (2005).
38. Voduc, D., Cheang, M. & Nielsen, T. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol. Biomarkers Prev. 17, 365–373 (2008).
39. Qian, X. L. et al. Caveolin-1: A multifaceted driver of breast cancer progression and its application in clinical treatment. Onco. Targets. Ther. 12, 1539–1552 (2019).
40. Coates, A. S. et al. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 26, 1533–1546 (2015).
41. Cheang, M. C. U. et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl. Cancer Inst. 101, 736–750 (2009).
42. Senkus, E. et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 26 Suppl 5, v8-30 (2015).
43. Kim, H. K. et al. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance. Cancer Res. Treat. 51, 737– 747 (2019).
44. van ’t Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002).
45. Cobleigh, M. A. et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin. cancer Res. an Off. J. Am. Assoc. Cancer Res. 11, 8623–8631 (2005).
46. Naoi, Y. & Noguchi, S. Multi-gene classifiers for prediction of recurrence in breast cancer patients. Breast Cancer 23, 12–18 (2016).
47. Wishart, D. S. et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34, D668-72 (2006).
48. Horak, C. E. et al. Biomarker analysis of neoadjuvant doxorubicin/ cyclophosphamide followed by ixabepilone or paclitaxel in early-stage breast cancer. Clin. Cancer Res. 19, 1587–1595 (2013).
49. Dezso, Z. et al. Gene expression profiling reveals Epithelial Mesenchymal Transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells. PLoS One (2014) doi:10.1371/journal.pone.0106131.
50. Dai, X., Xiang, L., Li, T. & Bai, Z. Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. J. Cancer 7, 1281–1294 (2016).
51. Choudhary, C. & Mann, M. Decoding signalling networks by mass spectrometry- based proteomics. Nat. Rev. Mol. Cell Biol. (2010) doi:10.1038/nrm2900.
52. Beltrao, P., Bork, P., Krogan, N. J. & Van Noort, V. Evolution and functional cross-talk of protein post-translational modifications. Mol. Syst. Biol. 9, 1–13 (2013).
53. Doll, S. & Burlingame, A. L. Mass spectrometry-based detection and assignment of protein posttranslational modifications. ACS Chem. Biol. 10, 63–71 (2015).
54. Riley, N. M. & Coon, J. J. Phosphoproteomics in the Age of Rapid and Deep Proteome Profiling. Anal. Chem. 88, 74–94 (2016).
55. Taylor, S. S. & Radzio-Andzelm, E. Three protein kinase structures define a common motif. Structure 2, 345–355 (1994).
56. Nolen, B., Taylor, S. & Ghosh, G. Regulation of protein kinases: Controlling activity through activation segment conformation. Mol. Cell 15, 661–675 (2004).
57. IWASAKI, M. & ISHIHAMA, Y. Challenges Facing Complete Human Proteome Analysis. CHROMATOGRAPHY 35, 73–80 (2014).
58. Breitkreutz, A. et al. A global protein kinase and phosphatase interaction network in yeast. Science 328, 1043–1046 (2010).
59. Gingras, A.-C., Gstaiger, M., Raught, B. & Aebersold, R. Analysis of protein complexes using mass spectrometry. Nat. Rev. Mol. Cell Biol. 8, 645–654 (2007).
60. Kaake, R. M., Wang, X. & Huang, L. Profiling of protein interaction networks of protein complexes using affinity purification and quantitative mass spectrometry. Mol. Cell. Proteomics 9, 1650–1665 (2010).
61. Rinner, O. et al. An integrated mass spectrometric and computational framework for the analysis of protein interaction networks. Nat. Biotechnol. 25, 345–352 (2007).
62. Gerber, S. A., Rush, J., Stemman, O., Kirschner, M. W. & Gygi, S. P. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. (2003) doi:10.1073/pnas.0832254100.
63. Lange, V., Picotti, P., Domon, B. & Aebersold, R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. (2008) doi:10.1038/msb.2008.61.
64. Picotti, P., Bodenmiller, B., Mueller, L. N., Domon, B. & Aebersold, R. Full Dynamic Range Proteome Analysis of S. cerevisiae by Targeted Proteomics. Cell (2009) doi:10.1016/j.cell.2009.05.051.
65. Bisson, N. et al. Selected reaction monitoring mass spectrometry reveals the dynamics of signaling through the GRB2 adaptor. Nat. Biotechnol. (2011) doi:10.1038/nbt.1905.
66. Dong, M.-Q. et al. Quantitative Mass Spectrometry Identifies Insulin Signaling Targets in <em>C. elegans</em> Science (80-. ). 317, 660 LP – 663 (2007).
67. Xiao, Y., Guo, L. & Wang, Y. A Targeted Quantitative Proteomics Strategy for Global Kinome Profiling of Cancer Cells and Tissues. Mol. Cell. Proteomics (2014) doi:10.1074/mcp.M113.036905.
68. Urisman, A. et al. An optimized chromatographic strategy for multiplexing in parallel reaction monitoring mass spectrometry: Insights from quantitation of activated kinases. Mol. Cell. Proteomics 16, 265–277 (2017).
69. Wolf-Yadlin, A., Hautaniemi, S., Lauffenburger, D. A. & White, F. M. Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc. Natl. Acad. Sci. (2007) doi:10.1073/pnas.0608638104.
70. Kennedy, J. J. et al. Immobilized Metal Affinity Chromatography Coupled to Multiple Reaction Monitoring Enables Reproducible Quantification of Phospho- signaling. Mol. Cell. Proteomics (2016) doi:10.1074/mcp.O115.054940.
71. Yang, T. Y., Eissler, C. L., Hall, M. C. & Parker, L. L. A Multiple Reaction Monitoring (MRM) Method to Detect Bcr-Abl Kinase Activity in CML Using a Peptide Biosensor. PLoS One 8, 1–10 (2013).
72. Shi, T. et al. Sensitive targeted quantification of ERK phosphorylation dynamics and stoichiometry in human cells without affinity enrichment. Anal. Chem. (2015) doi:10.1021/ac503797x.
73. Zhang, G. et al. Mass Spectrometry Mapping of Epidermal Growth Factor Receptor Phosphorylation Related to Oncogenic Mutations and Tyrosine Kinase Inhibitor Sensitivity. J. Proteome Res. 10, 305–319 (2011).
74. Atrih, A. et al. Stoichiometric quantification of Akt phosphorylation using LC- MS/MS. J. Proteome Res. (2010) doi:10.1021/pr900572h.
75. Hornbeck, P. V et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post- translational modifications in man and mouse. Nucleic Acids Res. 40, D261-70 (2012).
76. Fumio Matsuda. ターゲットプロテオーム解析をはじめるノウハウ A Practical Introduction to Targeted Proteomics. Proteome Lett. 1, 89–94 (2016).
77. McPhillips, F. et al. Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. Carcinogenesis 27, 729–739 (2006).
78. Yoshiki, S. et al. Ras and calcium signaling pathways converge at Raf1 via the Shoc2 scaffold protein. Mol. Biol. Cell 21, 1088–1096 (2010).
79. Zhao, Z., Tan, Z., Diltz, C. D., You, M. & Fischer, E. H. Activation of mitogen- activated protein (MAP) kinase pathway by pervanadate, a potent inhibitor of tyrosine phosphatases. J. Biol. Chem. 271, 22251–22255 (1996).
80. Matsumoto, M. et al. A large-scale targeted proteomics assay resource based on an in vitro human proteome. Nat. Methods 14, 251–258 (2017).
81. Hibi, M., Lin, A., Smeal, T., Minden, A. & Karin, M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c- Jun activation domain. Genes Dev. 7, 2135–2148 (1993).
82. Huang, J. et al. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 482, 542–546 (2012).
83. Wang, L., Dai, W. & Lu, L. Stress-induced c-Jun activation mediated by Polo-like kinase 3 in corneal epithelial cells. J. Biol. Chem. 282, 32121–32127 (2007).
84. Masuda, T., Tomita, M. & Ishihama, Y. Phase transfer surfactant-aided trypsin digestion for membrane proteome analysis. J. Proteome Res. (2008) doi:10.1021/pr700658q.
85. Sugiyama, N. et al. Phosphopeptide Enrichment by Aliphatic Hydroxy Acid- modified Metal Oxide Chromatography for Nano-LC-MS/MS in Proteomics Applications. Mol. Cell. Proteomics (2007) doi:10.1074/mcp.T600060-MCP200.
86. Rappsilber, J., Mann, M. & Ishihama, Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. (2007) doi:10.1038/nprot.2007.261.
87. Rappsilber, J., Ishihama, Y. & Mann, M. Stop And Go Extraction tips for matrix- assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal. Chem. (2003) doi:10.1021/ac026117i.
88. Kyono, Y., Sugiyama, N., Imami, K., Tomita, M. & Ishihama, Y. Successive and selective release of phosphorylated peptides captured by hydroxy acid-modified metal oxide chromatography. J. Proteome Res. (2008) doi:10.1021/pr800305y.
89. Boersema, P. J., Raijmakers, R., Lemeer, S., Mohammed, S. & Heck, A. J. R. Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. Nat. Protoc. (2009) doi:10.1038/nprot.2009.21.
90. Ishihama, Y., Rappsilber, J., Andersen, J. S. & Mann, M. Microcolumns with self- assembled particle frits for proteomics. in Journal of Chromatography A (2002). doi:10.1016/S0021-9673(02)01402-4.
91. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. (2008) doi:10.1038/nbt.1511.
92. Elias, J. E. & Gygi, S. P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat. Methods 4, 207– 214 (2007).
93. Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U. S. A. 95, 14863–14868 (1998).
94. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1–13 (2009).
論文の公開元へ
